Tyrone D Cannon1, Changhong Yu1, Jean Addington1, Carrie E Bearden1, Kristin S Cadenhead1, Barbara A Cornblatt1, Robert Heinssen1, Clark D Jeffries1, Daniel H Mathalon1, Thomas H McGlashan1, Diana O Perkins1, Larry J Seidman1, Ming T Tsuang1, Elaine F Walker1, Scott W Woods1, Michael W Kattan1. 1. From the Departments of Psychology and Psychiatry, Yale University, New Haven, Conn.; the Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland; the Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Alberta; the Departments of Psychiatry and Biobehavioral Sciences and Psychology, UCLA, Los Angeles; the Department of Psychiatry, UCSD, San Diego; the Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York; NIMH, Bethesda, Md.; the Renaissance Computing Institute, University of North Carolina, Chapel Hill; the Department of Psychiatry, UCSF, San Francisco; the Department of Psychiatry, University of North Carolina, Chapel Hill; the Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston; the Center for Behavioral Genomics, the Department of Psychiatry, and the Institute of Genomic Medicine, UCSD, La Jolla; and the Departments of Psychology and Psychiatry, Emory University, Atlanta.
Abstract
OBJECTIVE: Approximately 20%-35% of individuals 12-35 years old who meet criteria for a prodromal risk syndrome convert to psychosis within 2 years. However, this estimate ignores the fact that clinical high-risk cases vary considerably in risk. The authors sought to create a risk calculator, based on profiles of risk indicators, that can ascertain the probability of conversion to psychosis in individual patients. METHOD: The study subjects were 596 clinical high-risk participants from the second phase of the North American Prodrome Longitudinal Study who were followed up to the time of conversion to psychosis or last contact (up to 2 years). The predictors examined were limited to those that are supported by previous studies and are readily obtainable in general clinical settings. Time-to-event regression was used to build a multivariate model predicting conversion, with internal validation using 1,000 bootstrap resamples. RESULTS: The 2-year probability of conversion to psychosis was 16%. Higher levels of unusual thought content and suspiciousness, greater decline in social functioning, lower verbal learning and memory performance, slower speed of processing, and younger age at baseline each contributed to individual risk for psychosis. Stressful life events, trauma, and family history of schizophrenia were not significant predictors. The multivariate model achieved a concordance index of 0.71 and, as reported in an article by Carrión et al., published concurrently with this one, was validated in an independent external data set. The results are instantiated in a web-based risk prediction tool envisioned to be most useful in research protocols involving the psychosis prodrome. CONCLUSIONS: A risk calculator comparable in accuracy to those for cardiovascular disease and cancer is available to predict individualized conversion risks in newly ascertained clinical high-risk cases. Given that the risk calculator can be validly applied only for patients who screen positive on the Structured Clinical Interview for Psychosis Risk Syndromes, which requires training to administer, its most immediate uses will be in research on psychosis risk factors and in research-driven clinical (prevention) trials.
OBJECTIVE: Approximately 20%-35% of individuals 12-35 years old who meet criteria for a prodromal risk syndrome convert to psychosis within 2 years. However, this estimate ignores the fact that clinical high-risk cases vary considerably in risk. The authors sought to create a risk calculator, based on profiles of risk indicators, that can ascertain the probability of conversion to psychosis in individual patients. METHOD: The study subjects were 596 clinical high-risk participants from the second phase of the North American Prodrome Longitudinal Study who were followed up to the time of conversion to psychosis or last contact (up to 2 years). The predictors examined were limited to those that are supported by previous studies and are readily obtainable in general clinical settings. Time-to-event regression was used to build a multivariate model predicting conversion, with internal validation using 1,000 bootstrap resamples. RESULTS: The 2-year probability of conversion to psychosis was 16%. Higher levels of unusual thought content and suspiciousness, greater decline in social functioning, lower verbal learning and memory performance, slower speed of processing, and younger age at baseline each contributed to individual risk for psychosis. Stressful life events, trauma, and family history of schizophrenia were not significant predictors. The multivariate model achieved a concordance index of 0.71 and, as reported in an article by Carrión et al., published concurrently with this one, was validated in an independent external data set. The results are instantiated in a web-based risk prediction tool envisioned to be most useful in research protocols involving the psychosis prodrome. CONCLUSIONS: A risk calculator comparable in accuracy to those for cardiovascular disease and cancer is available to predict individualized conversion risks in newly ascertained clinical high-risk cases. Given that the risk calculator can be validly applied only for patients who screen positive on the Structured Clinical Interview for Psychosis Risk Syndromes, which requires training to administer, its most immediate uses will be in research on psychosis risk factors and in research-driven clinical (prevention) trials.
Authors: Danielle A Schlosser; Sarah Jacobson; Qiaolin Chen; Catherine A Sugar; Tara A Niendam; Gang Li; Carrie E Bearden; Tyrone D Cannon Journal: Schizophr Bull Date: 2011-08-08 Impact factor: 9.306
Authors: Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Phillip L Ross; Claudia Gerigk; Mithat Gonen; Ofer Yossepowitch; Ilias Cagiannos; Pramod C Sogani; Peter T Scardino; Michael W Kattan Journal: Semin Urol Oncol Date: 2002-05
Authors: G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger Journal: Arch Gen Psychiatry Date: 2010-02
Authors: I Janssen; L Krabbendam; M Bak; M Hanssen; W Vollebergh; R de Graaf; J van Os Journal: Acta Psychiatr Scand Date: 2004-01 Impact factor: 6.392
Authors: Richard S E Keefe; Terry E Goldberg; Philip D Harvey; James M Gold; Margaret P Poe; Leigh Coughenour Journal: Schizophr Res Date: 2004-06-01 Impact factor: 4.939
Authors: Cynthia B Solot; Tyler M Moore; Terrence Blaine Crowley; Marsha Gerdes; Edward Moss; Daniel E McGinn; Beverly S Emanuel; Elaine H Zackai; Sean Gallagher; Monica E Calkins; Kosha Ruparel; Ruben C Gur; Donna M McDonald-McGinn; Raquel E Gur Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2020-07-27 Impact factor: 3.568
Authors: Adam J Ciarleglio; Gary Brucato; Michael D Masucci; Rebecca Altschuler; Tiziano Colibazzi; Cheryl M Corcoran; Francesca M Crump; Guillermo Horga; Eugénie Lehembre-Shiah; Wei Leong; Scott A Schobel; Melanie M Wall; Lawrence H Yang; Jeffrey A Lieberman; Ragy R Girgis Journal: Psychol Med Date: 2018-06-28 Impact factor: 7.723
Authors: Lotta-Katrin Pries; Sinan Guloksuz; Margreet Ten Have; Ron de Graaf; Saskia van Dorsselaer; Nicole Gunther; Christian Rauschenberg; Ulrich Reininghaus; Rajiv Radhakrishnan; Maarten Bak; Bart P F Rutten; Jim van Os Journal: Schizophr Bull Date: 2018-06-06 Impact factor: 9.306
Authors: Jean Addington; Donald Addington; Sabina Abidi; Thomas Raedler; Gary Remington Journal: Can J Psychiatry Date: 2017-07-21 Impact factor: 4.356
Authors: Anthony W Zoghbi; Joel A Bernanke; Julia Gleichman; Michael D Masucci; Cheryl M Corcoran; Allegra Califano; Justin Segovia; Tiziano Colibazzi; Michael B First; Gary Brucato; Ragy R Girgis Journal: J Psychiatr Res Date: 2019-04-21 Impact factor: 4.791
Authors: Boris Birmaher; John A Merranko; Tina R Goldstein; Mary Kay Gill; Benjamin I Goldstein; Heather Hower; Shirley Yen; Danella Hafeman; Michael Strober; Rasim S Diler; David Axelson; Neal D Ryan; Martin B Keller Journal: J Am Acad Child Adolesc Psychiatry Date: 2018-08-07 Impact factor: 8.829
Authors: Eva Velthorst; Eric C Meyer; Anthony J Giuliano; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Larry J Seidman Journal: Schizophr Res Date: 2018-08-02 Impact factor: 4.939
Authors: Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306